Sugi Predict

Sugi Predict / Compounds / SCHEMBL7914435

SCHEMBL7914435

SCHEMBL7914435

Cc1ccc2[nH]c(C)nc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ NOS2 P35228 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ RAB9A P51151 2/20 0.37
▸ CCR1 P32246 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ ADRB2 P07550 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300137 0.78 SMN1; SMN2 (0.47) SMN1; SMN2NOS1ALDH1A1GAAKMT2A
SCHEMBL6299123 0.78 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1GAAADRB2HTT
SCHEMBL30490138 0.78 SMN1; SMN2 (0.47) SMN1; SMN2NOS1ALDH1A1GAAKMT2A
SCHEMBL17513474 0.78 NOS1 (0.39) SMN1; SMN2NOS1NOS2ALDH1A1GAA
SCHEMBL10140811 0.75 HSD17B10 (0.43) NOS1NOS2ALDH1A1GAAKMT2A
SCHEMBL12437102 0.75 SMN1; SMN2 (0.37) SMN1; SMN2ALDH1A1GAAADRB2HTT
SCHEMBL8312963 0.75 NOS1 (0.44) NOS1NOS2GAAKMT2APARP1
SCHEMBL22244252 0.75 DGAT2 (0.39) SMN1; SMN2NOS1NOS2ALDH1A1GAA
SCHEMBL9406894 0.75 ADORA1 (0.51) SMN1; SMN2NOS1NOS2ALDH1A1GAA
SCHEMBL6711042 0.74 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1RAB9AADRB2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 — — US disclosed
WO-2024130689-A1 2-FLUOROBIPHENYL-4-ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 江苏普莱医药生物技术有限公司 2024-06-27 — — WO disclosed
EP-4257591-A2 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2023-10-11 — — EP disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
EP-3080100-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-30 — — EP disclosed
CN-111556882-B Polymer additives for reducing viscosity loss upon tinting 巴斯夫欧洲公司 2022-10-04 — — CN disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 — — US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 — — US disclosed
US-20120076755-A1 Hepatitis C Virus Inhibitors ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 — — WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR SMN1; SMN2 1945/4885NOS1 3462/4885NOS2 3160/4885
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SMN1; SMN2 787/4885NOS1 1569/4885NOS2 2039/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SMN1; SMN2 1489/4885NOS1 1437/4885NOS2 1667/4885
US-20120076755-A1 Hepatitis C Virus Inhibitors NSUN2, HCCS, HAVCR2 SMN1; SMN2 4303/4885NOS1 2511/4885NOS2 2546/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A SMN1; SMN2 1995/4885NOS1 498/4885NOS2 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.